Skip to content

Author

Hoshiyar Singh

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Schiff-base cross-linked pullulan-chondroitin sulfate hydrogel incorporating raloxifene-poly(2-methyl-2-oxazoline) micelles for localized therapy of postmenopausal osteoarthritis.

Postmenopausal osteoarthritis (OA) is a degenerative joint disorder characterized by cartilage erosion and subchondral bone loss, intensified by estrogen deficiency in menopausal women. Raloxifene (RLX), a selective estrogen receptor modulator, shows anti-inflammatory and chondroprotective potential but is associated w...

Atul Mourya, Hoshiyar Singh, Shristi Arya et al. · 0 citations
Sep 2026

Spray drying-assisted development of hydroxypropyl methylcellulose acetate succinate microparticles for andrographolide delivery: an in-vivo study in experimental ulcerative colitis.

ADG-HPMC-AS MPs may serve as a promising drug-delivery system for improving the therapeutic potential of ADG in the effective management of UC and validate ADG-HPMC-AS MPs as a drug delivery system that ameliorates UC by attenuating oxidative stress and NF-kB/STAT3-driven signalling.

Pawan Devangan, Hoshiyar Singh, Soyal Sayyed et al. · 0 citations
Sep 2026

A Thieno[3,2-D] pyrimidine class of p110α/GDH1 dual inhibitor SBS-873 suppresses TNBC growth by inhibiting PI3K/mTOR signaling and inducing ferroptosis through glutathione depletion.

Findings identify SBS-873 as a first-in-class dual inhibitor targeting both p110α and GDH1, offering a promising therapeutic strategy that simultaneously disrupts proliferative signaling, metabolic adaptation, and metastatic potential in TNBC.

Biswajit Dey, Essha Chatterjee, Sivkan Kaur Nanda et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.